Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma

References

• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32. doi: 10.1182/blood-2014-05-577189.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. POLIVY® Summary of Product Characteristics 2022 [Accessed August 2023].
   Google Scholar
• U.S. Food and Drug Administration. POLIVY® Prescribing Information 2019 [Accessed December 2022].
   Google Scholar
• Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182(5):633–643. doi: 10.1111/bjh.15412.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. BREYANZI® US Prescribing Information 2022 [Accessed July 2023].
   Google Scholar
• Neelapu SS, Jacobson CA, Ghobadi A, et al. 5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). Blood. 2023;141(19):2307–2315. doi: 10.1182/blood.2022018893.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–1415. doi: 10.1016/S1470-2045(21)00375-2.
   PubMed Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988. doi: 10.1016/S1470-2045(20)30225-4.
   PubMed Web of Science ®Google Scholar
• Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220–2231. doi: 10.1056/NEJMoa2206913.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41(12):2238–2247. doi: 10.1200/jco.22.01725.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–e265. doi: 10.1016/S2352-3026(19)30026-2.
   PubMed Web of Science ®Google Scholar
• Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800. doi: 10.1016/S1470-2045(21)00139-X.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Bell JA, Hamilton L, et al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol. 2018;14(25):2627–2642. doi: 10.2217/fon-2018-0267.
   PubMed Web of Science ®Google Scholar
• Purdum A, Tieu R, Reddy SR, et al. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229–1236. doi: 10.1634/theoncologist.2018-0490.
   PubMed Web of Science ®Google Scholar
• Ren J, Asche CV, Shou Y, et al. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. J Comp Eff Res. 2019;8(6):393–402. doi: 10.2217/cer-2018-0094.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: effectiveness and Value. 2018. Available at: https://icer.org/wp-content/uploads/2020/10/ICER_CAR_T_Final_Evidence_Report_032318.pdf. [Accessed: January 19, 2024].
   Google Scholar
• Sahli B, Eckwright D, Pp G Chimeric Antigen Receptor T-cell (CAR-T) Therapy Real-World Assessment of Total Cost of Care and Clinical Events for the Treatment of Relapsed or Refractory Lymphoma among 15 Million Commercially Insured Members. Presented at the Academy of Managed Care Pharmacists (AMCP) Annual Meeting 2021 [Accessed 02 October, et al. 2023].
   Google Scholar
• To T, Gu J, Li J, et al. Do patients with diffuse large B-cell lymphoma (DLBCL) receive treatments consistent with national comprehensive cancer network (NCCN) guidelines and what are the total costs of care? Value Health. 2019;22(S1):S94. doi: 10.1016/j.jval.2019.04.326.
   Google Scholar
• Danese MD, Griffiths RI, Gleeson ML, et al. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leuk Lymphoma. 2017;58(5):1094–1104. doi: 10.1080/10428194.2016.1228924.
   PubMed Web of Science ®Google Scholar
• Reyes C, Gauthier G, Shi S, et al. Overall survival and health care costs of medicare patients with previously treated chronic lymphocytic leukemia. JCT. 2018;09(07):576–587. doi: 10.4236/jct.2018.97049.
   Google Scholar
• Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project Chronic Condition Indicator Refined (CCIR) for ICD-10-CM December 2022 [Accessed 22 September 2023].
   Google Scholar
• US Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers: Medical Care in U.S. City Average. Retrieved from FRED, Federal Reserve Bank of St. Louis; https://fred.stlouisfed.org/series/CPIMEDSL. Accessed 09 February 2024].
   Google Scholar
• Jacobsen GD, Jacobsen KH. Statewide COVID-19 stay-at-home orders and population mobility in the United States. World Med Health Policy. 2020;12(4):347–356. doi: 10.1002/wmh3.350.
   PubMed Web of Science ®Google Scholar
• R Core Team. 2023. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. https://www.R-project.org/. [Accessed 09 February 2024].
   Google Scholar
• Tkacz J, Garcia J, Gitlin M, et al. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy. Leuk Lymphoma. 2020;61(7):1601–1609. doi: 10.1080/10428194.2020.1734592.
   PubMed Web of Science ®Google Scholar
• Mutebi A, Jun M, Flores C, et al. Real-world treatment patterns and costs in relapsed and refractory diffuse large B-cell lymphoma in the United States. Value Health. 2022;25(7):S394. doi: 10.1016/j.jval.2022.04.553.
   Google Scholar
• Yang X, Laliberté F, Germain G, et al. Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B-cell lymphoma in the U.S. Oncologist. 2021;26(5):e817–e826. doi: 10.1002/onco.13721.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42. doi: 10.1016/S1470-2045(18)30864-7.
   PubMed Web of Science ®Google Scholar
• Hoffmann MS, Hunter BD, Cobb PW, et al. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma. Transplant Cell Ther. 2023;29(7):440–448. doi: 10.1016/j.jtct.2023.04.003.
   PubMedGoogle Scholar
• Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073. doi: 10.1200/jco.2013.51.5866.
   PubMed Web of Science ®Google Scholar
• Jakobsen LH, Bøgsted M, Brown P, et al. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. J Clin Oncol. 2017;35(7):778–784. doi: 10.1200/jco.2016.70.0765.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29(8):1822–1827. doi: 10.1093/annonc/mdy203.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–363. doi: 10.1056/NEJMoa2115304.
   PubMed Web of Science ®Google Scholar
• Herbaux C, Dietrich S, McMillan A, et al. Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: descriptive analysis of POLARIX. Hematol Oncol. 2023;41(S2):432–433. doi: 10.1002/hon.3164_318.
   Google Scholar